This review summarizes the latest findings in the literature of Angiopoietin-2 
(Ang-2), Tyrosine-protein kinase receptor (Tie-2) complex, and faricimab along 
with their involvement for the treatment of retinal vascular diseases in various 
clinical trials. In ischemic diseases, such as diabetic retinopathy, Ang-2 is 
upregulated, deactivating Tie-2, resulting in vascular leakage, pericyte loss, 
and inflammation. Recombinant Angiopeotin-1 (Ang-1), Ang-2-blocking molecules, 
and inhibitors of vascular endothelial protein tyrosine phosphatase (VE-PTP) 
decrease inflammation-associated vascular leakage, showing therapeutic effects 
in diabetes, atherosclerosis, and ocular neovascular diseases. In addition, 
novel studies show that angiopoietin-like proteins may play an important role in 
cellular metabolism leading to retinal vascular diseases. Current therapeutic 
focus combines Ang-Tie targeted drugs with other anti-angiogenic or immune 
therapies. Clinical studies have identified faricimab, a novel bispecific 
antibody designed for intravitreal use, to simultaneously bind and neutralize 
Ang-2 and VEGF-A for treatment of diabetic eye disease. By targeting both Ang-2 
and vascular endothelial growth factor-A (VEGF-A), faricimab displays an 
improved and sustained efficacy over longer treatment intervals, delivering 
superior vision outcomes for patients with diabetic macular edema and reducing 
the treatment burden for patients with neovascular age-related macular 
degeneration and diabetic macular edema. Phase 2 results have produced promising 
outcomes with regard to efficacy and durability. Faricimab is currently being 
evaluated in global Phase 3 studies.